Hepatocyte growth factor (HGF), a natural ligand for the c-met proto oncogene product, exhibits mitogenic, mo togenic, and morphogenic activities for regeneration of the liver, kidney, and lung. Recently, HGF was clearly shown to enhance neurite outgrowth in vitro. To determine whether HGF has a neuroprotective action against the death of neurons in vivo, we studied the effect of HGF on delayed neuronal death in the hippocampus after 5-minute transient forebrain ischemia in Mongolian gerbils. Continuous postischemic intrastriatal ad ministration of human recombinant HGF (10 or 30 /J-g) for 7 days potently prevented the delayed death of hippocampal neu-
Hepatocyte growth factor (HGF) is a pleiotrophic cy tokine that exhibits mitogenic, motogenic, and morpho genic activities toward a variety of cells (Nakamura et aI., 1989; Zarnegar and Michalopoulos, 1995; Matsu moto and Nakamura, 1996) . Physiologically, HGF plays an important role as an organotrophic factor responsible for vigorous regeneration of the liver, kidney, and lung (Nakamura et aI., 1989; Boros and Miller, 1995; Zarnegar and Michalopoulos, 1995; Matsumoto and Na kamura, 1996) . Both HGF and the c-Met/HGF receptor of membrane-spanning tyrosine kinase are expressed in various regions of the brain, and functional coupling be tween HGF and c-Met enhances the survival of hippo-rons under both anesthetized and awake conditions. Even when HGF infusion started 6 hours after ischemia (i.e., in a delayed manner), HGF exhibited a neuroprotective action. We conclude that HGF, a novel neurotrophic factor, has a profound neuro protective effect against postischemic delayed neuronal death in the hippocampus, which may have implications for the de velopment of new therapeutic strategies for ischemic neuronal damage in humans. Key Words: Hepatocyte growth factor c-Met-Cerebral ischemia-Hippocampus-Delayed neuronal death-Gerbi 1.
campal neurons in primary culture and induces neurite outgrowth on neuronal development in vitro (lung et aI., 1994; Honda et aI., 1995; Yamagata et aI., 1995; Hamanoue et aI., 1996) . Hepatocyte growth factor plays a role as a limb mesenchyme-derived chemoattractant for motor axons (Ebens et aI., 1996) , and is as potent a survival factor for motor neurons as other survival fac tors described to date, such as brain-derived neurotrophic factor (Oppenheim et aI., 1992) , ciliary neurotrophic fac tor (Sendtner et aI., 1992) , and glial cell line-derived neurotrophic factor (Henderson et aI., 1994) . This accu mulating evidence implies a neurotrophic function of HGF; however, there have been no reports on whether HGF exhibits neurotrophic activity in vivo. In the current study, to determine whether HGF has a neuroprotective action against the death of neurons in vivo, we studied the effect of HGF on delayed neuronal death after tran sient forebrain ischemia in gerbils (Kirino, 1982) using continuous topical administration of HGF directly into the brain (Miyazawa et aI., 1997) . 
METHODS

Animal preparation
Fifty-eight male Mongolian gerbils weighing 50 to 70 g were used and divided into eight experimental groups. Anesthesia was performed with an initial concentration of 3% halothane, and then maintained with 1.5% halothane in a mixture of 40% 02/60% N20 under a face mask. In experiments 1 and 2, a needle electrode was placed in the subscalpal space for EEG recording to confirm electrical cessation during ischemia. The body temperature was monitored and maintained at 37°C throughout the experiments using a feedback-controlled heat ing pad. or a physiologic saline solution was implanted. A cannula de vice connected to the subcutaneously implanted osmotic mini pump was inserted into the right striatum from a point I mm anterior, 2 mm lateral, and 4 mm ventral to the bregma, and fixed with dental cement to the skull. To start infusion just after implantation, each osmotic mini pump was incubated in physi ologic saline at 37°C according to the instructions of Alzet. The HGF was intrastriatally administered for I week during reper fusion. Approximately 30 minutes after implantation of the pump, both carotid arteries were occluded for 5 minutes with Sugita temporary aneurysm clips. Complete forebrain ischemia was confirmed by the electrical cessation on EEG. The animals were divided into four groups as follows:
Group I (n = 6): Sham-operated animals. The sham operation included carotid manipulation and cannula placement in the right striatum. Group 2 (n = 9): Ischemia and implantation of a minipump containing physiologic saline solution Group 3 (n = 9): Ischemia and implantation of a minipump containing 10 fLg HGF Group 4 (n = 9): Ischemia and implantation of a mini pump containing 30 fLg HGF Experiment 2: Delayed start of continuous intrastriatal administration of hepatocyte growth factor Animals were subjected to 5-minute transient forebrain isch emia similar to that in experiment I. After recovery from the anesthesia, the animals were returned to their cages and given free access to water. Six hours after the beginning of recircu lation, an osmotic mini pump including 30 fLg HGF was im planted under halothane reanesthesia. The osmotic minipump had been incubated in physiologic saline at 37°C before the experiment. Thus, the administration of HGF started 6 hours after ischemia and continued for 7 days (group 5, n = 9). Group 2 was used as a control group. To exclude the possibility of a secondary neuroprotective effect of halothane per se (Edgehouse and Dorman, 1987) and postischemic secondary hypothermia (Corbett et a!., 1990; Kuroiwa et a!., 1990) , animals were subjected to ischemia un der awake conditions. Anesthesia was initially performed and an osmotic minipump was implanted without incubation. To accomplish awake forebrain ischemia, the first thread was J Cereb Blood Flow Metah, Vol. 18, No.4, 1998 looped around both common carotid arteries, while the second thread was ligated on the loop. The ends of the first thread were led out through the nuchal muscle and back skin, and then left until the start of ischemia. After closure of the wounds halo thane inhalation was discontinued, followed by at least 2 hours until complete recovery from the anesthesia. The animals were subjected to S-rninute forebrain ischemia under awake condi tions, without any pain, by occlusion of both common carotid arteries by pulling the ends of the first thread. The loss of the righting reflex was taken as evidence of forebrain ischemia under awake conditions. The ends of the second thread were pulled to release the carotid occlusion. In this experiment, since the osmotic minipumps were not incubated at 37°C, the infu sion usually started 3 to 4 hours after implantation (i.e., I to 2 hours after ischemia). The animals were divided into two groups as follows:
Group 6 (n = 7): Awake ischemia and implantation of a minipump containing physiologic saline solution Group 7 (n = 7): Awake ischemia and implantation of a mini pump containing 30 fLg HGF In the animals in group 8 (n = 2), 30 fLg HGF was infused for 7 days into the striatum without ischemia; the brains were investigated pathologically to determine whether HGF had a toxic effect on glia and neurons of the striatum. Coronal sec tions of the two brains, passing through the trajectory of the cannula in the striatum, were stained with hematoxylin and eosin for pathologic observation.
Evaluation
Seven days after ischemia, the animals were transcardially perfused with 4% paraformaldehyde in 0.01 moUL phosphate buffered saline. Infusion of the agent into the striatum was confirmed by the implanted pump being empty when the ani mals were killed. The brains were removed, immersed in the same fixative for 24 hours, and then embedded in paraffin. Three-micrometer paraffin sections were stained with cresyl violet. The number of intact neurons in the center of the hip pocampal CA I sector was determined, averaged, and expressed as both the neuronal density per 1 mm linear length. The in vestigator performing the cell counting was blind with regard to the treatment of each section. Statistical significance was analyzed using one-factor analysis of variance, followed by Scheffe's F test. Data are expressed as means ± SD (Fig. 1) .
RESULTS AND DISCUSSION
The current results constitute the first hard evidence that HGF can potently protect hippocampal neurons from ischemic insult in vivo. At first, gerbils were subjected to transient forebrain ischemia under halothane anesthesia, and then human recombinant HGF or saline was infused using an osmotic minipump. The absolute values per 1 mm of intact neurons in a bilateral CA 1 sector of the hippocampus after 7 days of reperfusion are given in Fig.  1 . In control animals infused with saline (group 2), only 3% to 4% of the neurons survived compared with sham operated animals (group 1) after forebrain ischemia. In contrast, continuous intrastriatal administration of HGF ischemia and implantation of a minipump containing PSS. Group 3 (n = 9): ischemia and implantation of a minipump containing 10 /-Ig HGF. Group 4 (n = 9): ischemia and implantation of a minipump containing 30 /-Ig HGF. Group 5 (n = 9): delayed start of HGF infusion 6 hours after ischemia. Group 6 (n = 7): awake ischmeia and implantation of a minipump containing PSS. Group 7 (n = 7): awake ischemia and implantation of a minipump con taining 30 /-Ig HGF. Statistical differences were evaluated by one factor analysis of variance followed by Scheffe's F-test. Groups 3, 4, and 5 were compared with group 2 on each side. Group 7 was compared with group 6 on each side. a, b, c, and d: P < 0.001 versus group 2; e and f: P < 0.05 versus group 2; g and h: P < 0.01 versus group 6. for 7 days during reperfusion prevented the delayed neu ronal death in a dose-dependent manner (groups 3 and 4). In animals infused with 30 f.Lg HGF (group 4), approxi mately two thirds of the neurons survived compared with sham-operated animals, with the number of surviving neurons being approximately 20-fold higher than in sa line-infused animals.
With regard to the clinical application of neurotrophic factors, they must be neuroprotective when administered after, not before or during, cerebral ischemia. In most studies on the neuroprotective effects of neurotrophic factors on a brain ischemia model, however, the neuro trophic factors usually were administered before the ini tiation of ischemia (Shigeno et aI., 1991; Beck et aI., 1994; Tsukahara et aI., 1994) . We therefore examined whether HGF has a neuroprotective action, even when HGF infusion started 6 hours after forebrain ischemia. About a quarter of the neurons survived in animals sub jected to delayed HGF infusion (group 5), which was approximately sevenfold higher than in control saline infused animals. Thus, the delayed infusion of HGF sig nificantly prevented the delayed neuronal death of CA I pyramidal neurons after forebrain ischemia. The signifi cant neuroprotection by HGF infused in a delayed man ner is encouraging for the practical application of HGF for the treatment of patients with ischemic neuronal in jury.
During the verification of neuroprotective agents, the neuroprotective effects of halothane per se (Edgehouse and Dorman, 1987) and postanesthetic secondary hypo thermia (Corbett et aI., 1990; Kuroiwa et aI., 1990) were found to frequently modify experimental results. To ex clude the possibility of such secondary neuroprotective effects, animals were subjected to ischemia under awake conditions. At 2 hours after discontinuation of anesthe sia, the animals were subjected to 5-minute forebrain ischemia under awake conditions. The HGF infusion substantially began by 1 to 2 hours after ischemia. In the ischemic animals under awake conditions, 30 f.Lg HGF significantly prevented the delayed neuronal death even after awake ischemia (group 7) compared with the data for the control group (group 6), thereby indicating that the neuroprotective effect of HGF did not result from postanesthetic secondary hypothermia or halothane per se. Furthermore, the fact that ischemia probably was more severe under awake conditions than under halo thane anesthesia (Imon et aI., 1991) strongly supports the neuroprotective effect of HGF.
Since hippocampal CAl neurons in rats express c-Met mRNA and HGF prolongs the survival of hippocampal neurons in primary culture (Honda et aI., 1995) , we pre sume that the neuroprotective action of HGF on CAl neurons is mediated by c-Met. Yamagata and others (1995) demonstrated selective HGF mRNA expression in the microglia of rat brain, and c-Met mRNA expres sion in neurons as well as in astrocytes and microglia. This also implies the possibility of interactions between neurons, astrocytes, and microglia through HGF and its receptor. In our study, the influence of long-lasting post ischemic mild hypothermia from HGF per se could not be completely excluded (Dietrich et aI., 1993; Colbourne and Corbett, 1994) , and we do not have data on the effect of HGF at the chronic stage (l to 2 months after isch emia). Since previous studies clearly demonstrate a neu rotrophic effect of HGF on neurons in primary culture under strict control through the medium temperature (Honda et aI., 1995) , we believe that the neurotrophic effect of HGF after forebrain ischemia persists longer, rather than that HGF delays the progression of "delayed neuronal death," as seen in hypothermic animals (Diet rich et aI., 1995) .
It is crucial to determine the appropriate amount of each neurotrophic factor for the neuroprotective action according to either the type of ischemic model or the mode of administration. Since there was no degenerative change of neurons or glia around the trajectory of the cannula, except for the traumatic injury caused by the cannula penetration, a toxic effect of HGF per se could be excluded (experiment 4, data not shown). Although the exact cellular mechanism of the neuroprotective ac tivity of HGF is not known, our results should facilitate further studies on different modes of HGF administration T. MIYAZA WA ET AL.
as well as on the effective time window for the neuro protective action of HGF toward ischemic neuronal in jury.
